HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Ligands of the peroxisome proliferator-activated receptors (PPAR-gamma and PPAR-alpha) reduce myocardial infarct size.

Abstract
This study was designed to investigate the effects of various chemically distinct activators of PPAR-gamma and PPAR-alpha in a rat model of acute myocardial infarction. Using Northern blot analysis and RT-PCR in samples of rat heart, we document the expression of the mRNA for PPAR-gamma (isoform 1 but not isoform 2) as well as PPAR-beta and PPAR-alpha in freshly isolated cardiac myocytes and cardiac fibroblasts and in the left and right ventricles of the heart. Using a rat model of regional myocardial ischemia and reperfusion (in vivo), we have discovered that various chemically distinct ligands of PPAR-gamma (including the TZDs rosiglitazone, ciglitazone, and pioglitazone, as well as the cyclopentanone prostaglandins 15D-PGJ2 and PGA1) cause a substantial reduction of myocardial infarct size in the rat. We demonstrate that two distinct ligands of PPAR-alpha (including clofibrate and WY 14643) also cause a substantial reduction of myocardial infarct size in the rat. The most pronounced reduction in infarct size was observed with the endogenous PPAR-gamma ligand, 15-deoxyDelta12,14-prostagalndin J2 (15D-PGJ2). The mechanisms of the cardioprotective effects of 15D-PGJ2 may include 1) activation of PPAR-alpha, 2) activation of PPAR-gamma, 3) expression of HO-1, and 4) inhibition of the activation of NF-kappaB in the ischemic-reperfused heart. Inhibition by 15D-PGJ2 of the activation of NF-kappaB in turn results in a reduction of the 1) expression of inducible nitric oxide synthase and the nitration of proteins by peroxynitrite, 2) formation of the chemokine MCP-1, and 3) expression of the adhesion molecule ICAM-1. We speculate that ligands of PPAR-gamma and PPAR-alpha may be useful in the therapy of conditions associated with ischemia-reperfusion of the heart and other organs. Our findings also imply that TZDs and fibrates may help protect the heart against ischemia-reperfusion injury. This beneficial effect of 15D-PGJ2 was associated with a reduction in the expression of the 1) adhesion molecules ICAM-1 and P-selectin, 2) chemokine macrophage chemotactic protein 1, and 3) inducible isoform of nitric oxide synthase. 15D-PGJ2 reduced the nitration of proteins (immunohistological analysis of nitrotyrosine formation) caused by ischemia-reperfusion, likely due to the generation of peroxynitrite. Not all of the effects of 15D-PGJ2, however, are due to the activation of PPAR-gamma. For instance, exposure of rat cardiac myocytes to 15D-PGJ2, but not to rosiglitazone, results in an up-regulation of the expression of the mRNA for heme-oxygenase-1 (HO-1). Taken together, these results provide convincing evidence that several, chemically distinct ligands of PPAR-gamma reduce the tissue necrosis associated with acute myocardial infarction.
AuthorsNicole S Wayman, Yoshiyuki Hattori, Michelle C McDonald, Helder Mota-Filipe, Salvatore Cuzzocrea, Babrbara Pisano, Prabal K Chatterjee, Christoph Thiemermann
JournalFASEB journal : official publication of the Federation of American Societies for Experimental Biology (FASEB J) Vol. 16 Issue 9 Pg. 1027-40 (Jul 2002) ISSN: 1530-6860 [Electronic] United States
PMID12087064 (Publication Type: Journal Article)
Chemical References
  • 15-deoxy-delta(12,14)-prostaglandin J2
  • Cardiotonic Agents
  • Cell Adhesion Molecules
  • Chemokine CCL2
  • Ligands
  • Membrane Proteins
  • Prostaglandins A
  • Protein Isoforms
  • Pyrimidines
  • RNA, Messenger
  • Receptors, Cytoplasmic and Nuclear
  • Thiazoles
  • Thiazolidinediones
  • Transcription Factors
  • Rosiglitazone
  • pirinixic acid
  • HMOX1 protein, human
  • Heme Oxygenase (Decyclizing)
  • Heme Oxygenase-1
  • Clofibrate
  • Prostaglandin D2
  • ciglitazone
  • prostaglandin A1
  • Pioglitazone
Topics
  • Adult
  • Animals
  • Cardiotonic Agents (pharmacology, therapeutic use)
  • Cell Adhesion Molecules (biosynthesis, genetics)
  • Cell Line
  • Cells, Cultured
  • Chemokine CCL2 (biosynthesis, genetics)
  • Clofibrate (therapeutic use)
  • Heme Oxygenase (Decyclizing) (genetics, physiology)
  • Heme Oxygenase-1
  • Humans
  • Ligands
  • Male
  • Membrane Proteins
  • Myocardial Infarction (drug therapy, metabolism, pathology)
  • Myocardial Reperfusion Injury (drug therapy, metabolism, pathology)
  • Pioglitazone
  • Prostaglandin D2 (analogs & derivatives, pharmacology, therapeutic use)
  • Prostaglandins A (therapeutic use)
  • Protein Isoforms (biosynthesis, genetics)
  • Pyrimidines (therapeutic use)
  • RNA, Messenger (biosynthesis)
  • Rats
  • Rats, Wistar
  • Receptors, Cytoplasmic and Nuclear (agonists, biosynthesis, genetics)
  • Rosiglitazone
  • Thiazoles (therapeutic use)
  • Thiazolidinediones
  • Transcription Factors (agonists, biosynthesis, genetics)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: